Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

CVS Profits Drop 20% for Quarter

November 3, 2010 6:24 am | by Matthew Perrone | News | Comments

CVS Caremark Corp. reported a drop in third-quarter profit as its pharmacy benefit unit continued losing business from previously canceled contracts.

TOPICS:

Biogen Cutting 13% of Work Force

November 3, 2010 6:23 am | News | Comments

Biotechnology company Biogen Idec Inc. said it is laying off 13 percent of its work force, or 650 employees, in a restructuring and cost-cutting move. Weston, Mass. based Biogen will have 4,275 employees after the cuts.

TOPICS:

Gilead Therapies Suppress HCV

November 2, 2010 8:54 am | News | Comments

Gilead Sciences, Inc. announced data from a Phase 2a study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus.

TOPICS:
Advertisement

Cell Therapeutics Submits MAA to EMA

November 2, 2010 8:48 am | News | Comments

Cell Therapeutics, Inc. announced that it has submitted a marketing authorization application to the European Medicines Agency for Pixuvri for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.

TOPICS:

FDA Grants CF Drug Orphan Drug Status

November 2, 2010 8:37 am | News | Comments

Discovery Laboratories, Inc. announced that the Food and Drug Administration has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis.

TOPICS:

NuPathe Submits Zelrix NDA

November 2, 2010 8:34 am | News | Comments

NuPathe Inc. announced that the company submitted a New Drug Application for Zelrix to the U.S. Food and Drug Administration. Zelrix is the first ever submission to the FDA of a transdermal patch for the treatment of migraine.

TOPICS:

XOMA Discussing Botulinum Toxin Treatment

November 2, 2010 8:29 am | News | Comments

XOMA Ltd announced several presentations that will highlight advances in the company's biodefense program and particularly in the development of XOMA 3AB, an antibody co-mixture that binds to distinct regions of botulinum toxin type A.

TOPICS:

Hyperion UCD Drug Succeeds in Phase 3 Study

November 2, 2010 8:21 am | News | Comments

Hyperion Therapeutics, Inc. announced that the company’s phase 3 pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders, met its primary endpoint.

TOPICS:
Advertisement

Antisense Publishes Phase 2b Trial Results

November 2, 2010 8:17 am | News | Comments

The investigated drug trabedersen (AP 12009) is a gene silencing antisense compound – a phosphorothioate oligodeoxynucleotide – designed to selectively downregulate the production of transforming growth factor-beta 2 (TGF-?2) at the translational level.

TOPICS:

NIR Camera

November 2, 2010 7:50 am | Drug Discovery & Development | Product Releases | Comments

Photometrics, a designer and manufacturer of high-performance CCD and EMCCD cameras for the life sciences, has exclusively integrated eXcelon sensor technology in its Evolve 512 and 128 EMCCD cameras.

TOPICS:

CNV Platform

November 2, 2010 7:43 am | Product Releases | Comments

NanoString Technologies, Inc. announced the launch of a novel solution for detecting genetic copy number variations associated with disease susceptibility, drug response, and cancer progression.

TOPICS:

Horizon and Mirna Collaborating on miRNA Mimics

November 2, 2010 7:30 am | News | Comments

Horizon Discovery and Mirna Therapeutics announced that they have entered into a collaboration agreement to test the impact of Mirna’s proprietary miRNA mimics on a panel of Horizon’s patient-relevant human isogenic cancer cell models.

TOPICS:

RecipharmCobra Eligible for R & D Tax Credits

November 2, 2010 7:17 am | News | Comments

RecipharmCobra Biologics, an international manufacturer of biopharmaceuticals, announces that the French Ministry for Higher Education and Research has recognised RecipharmCobra as an approved research and development service provider.

TOPICS:

Lung Cancer Requires Personalized Treatment

November 2, 2010 7:11 am | News | Comments

Rather than a “one-size-fits-all” treatment plan, researchers say lung cancer patients should receive care based on their specific diagnosis, individual genetic makeup and particular tumors.

TOPICS:

Omega-3 Fails Memory Test

November 2, 2010 7:05 am | by Lindsay Tanner | News | Comments

Omega-3 pills promoted as boosting memory didn't slow mental and physical decline in older patients with Alzheimer's disease, a big disappointment in a multimillion-dollar government-funded study.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading